Cell differentiation, caspase inhibition, and macromolecular synthesis blockage, but not BCL-2 or BCL-XL proteins, protect SH-SY5Y cells from apoptosis triggered by two CDK inhibitory drugs

Experimental Cell Research

Volumn 295, Issue 1, 2004, Pages 9-24

  Ribas, Judit ^a   Boix, Jacint ^a  

^a Universitat de Lleida Facultat de Medicina Sabadell   (Spain)

Author keywords

Apoptosis; Bcl 2; Bcl XL; Caspase; CDK; Cycloheximide; Erk; Olomoucine; Roscovitine; SH SY5Y

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CASPASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR; DACTINOMYCIN; MITOGEN ACTIVATED PROTEIN KINASE 1; OLOMOUCINE; PROTEIN BCL 2; PROTEIN BCL XL; ROSCOVITINE; UO 126;

APOPTOSIS; ARTICLE; CELL COUNT; CELL CULTURE; CELL DIFFERENTIATION; CELL LINE; CELL PROTECTION; CELL SUBPOPULATION; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; MACROMOLECULE; NEUROBLASTOMA; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 1642502384     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2003.12.019     Document Type: Article

References (47)

1. Manning G., Whyte D.B., Martinez R., Hunter T., Sudarsanam S. The protein kinase complement of the human genome. Science. 298:2002;1912-1934.
2. Norbury C., Nurse P. Animal cell cycles and their control. Annu. Rev. Biochem. 61:1992;441-470.
3. Hardcastle I.R., Golding B.T., Griffin R.J. Designing inhibitors of cyclin-dependent kinases. Annu. Rev. Pharmacol. Toxicol. 42:2002;325-348.
4. Knockaert M., Greengard P., Meijer L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol. Sci. 23:2002;417-425.
5. Sausville E.A. Complexities in the development of cyclin-dependent kinase inhibitor drugs. Trends Mol. Med. 8:2002;S32-S37.
6. Vesely J., Havlicek L., Strnad M., Blow J.J., Donella-Deana A., Pinna L., Letham D.S., Kato J., Detivaud L., Leclerc S., Meijer L. Inhibition of cyclin-dependent kinases by purine analogues. Eur. J. Biochem. 224:1994;771-786.
7. Meijer L., Borgne A., Mulner O., Chong J.P.J., Blow J.J., Inagaki N., Inagaki M., Delcros J.G., Molinoux J.P. Biochemical and cellular effects of roscovitine, a potent and selective inhibitor of the cyclin-dependent kinases cdc2, cdk2 and cdk5. Eur. J. Biochem. 243:1997;527-536.
8. Garrett M.D., Fattaey A. CDK inhibition and cancer therapy. Curr. Opin. Genet. Dev. 1999;104-111.
9. Yuste V.J., Sanchez-Lopez I., Sole C., Encinas M., Bayascas J.R., Boix J., Comella J.X. The prevention of the staurosporine-induced apoptosis by Bcl-X(L), but not by Bcl-2 or caspase inhibitors, allows the extensive differentiation of human neuroblastoma cells. J. Neurochem. 80:2002;126-139.
10. Cryns V., Yuan J. Proteases to die for. Genes Dev. 12:1998;1551-1570.
11. Thornberry N.A., Lazebnik Y. Caspases: enemies within. Science. 281:1998;1312-1316.
12. Alnemri E.S., Livingston D.J., Nicholson D.W., Salvesen G., Thornberry N.A., Wong W.W., Yuan J. Human ICE/CED-3 protease nomenclature. Cell. 87:1996;171.
13. Fischer U., Jänicke R.U., Schulze-Osthoff K. Many cuts to ruin: a comprehensive update of caspase substrates. Cell Death Differ. 10:2003;76-100.
14. Ashkenazi A., Dixit V.M. Death receptors: signaling and modulation. Science. 281:1998;1305-1308.
15. Adams J.M., Cory S. Apoptosomes: engines for caspase activation. Curr. Opin. Cell Biol. 14:1998;715-720.
16. Adams J.M., Cory S. The Bcl-2 protein family: arbiters of cell survival. Science. 281:1998;1322-1326.
17. Boix J., Llecha N., Yuste V.J., Comella J.X. Characterization of the cell death process induced by staurosporine in human neuroblastoma cell lines. Neuropharmacology. 36:1997;811-821.
18. Yuste V.J., Bayascas J.R., Llecha N., Sanchez-Lopez I., Boix J., Comella J.X. The absence of oligonucleosomal DNA fragmentation during apoptosis of IMR-5 neuroblastoma cells: disappearance of the caspase-activated DNase. J. Biol. Chem. 276:2001;22323-22331.
19. Encinas M., Iglesias M., Liu Y., Wang H., Muhaisen A., Ceña V., Gallego C., Comella J.X. Sequential treatment of SH-SY5Y cells with retinoic acid and brain-derived neurotrophic factor gives rise to fully differentiated, neurotrophic factor-dependent, human neuron-like cells. J. Neurochem. 75:2002;991-1003.
20. Wolfe J.T., Pringle J.H., Cohen G.M. Assays for the measurement of DNA fragmentation during apoptosis. Cotter T.G., Martin S.J. Techniques in Apoptosis. 1996;51-69 Portland Press, London.
21. Piqué M., Barragán M., Dalmau M., Bellosillo B., Pons G., Gil J. Aspirin induces apoptosis through mitochondrial cytochrome c release. FEBS Lett. 480:2000;193-196.
22. Knockaert M., Lenormand P., Gray N., Schultz P., Pouyssegur J., Meijer L. p42/p44 MAPKs are intracellular targets of the CDK inhibitor purvalanol. Oncogene. 21:2002;6413-6424.
23. 2+ and calmodulin. Mol. Cell. Biol. 20:2000;1931-1946.
24. Achenbach T.V., Muller R., Slater E.P. Bcl-2 independence of flavopiridol-induced apoptosis. Mitochondrial depolarization in the absence of cytochrome c release. J. Biol. Chem. 275:2002;32089-32097.
25. Pepper C., Thomas A., Hoy T., Fegan C., Bentley P. Flavopiridol circumvents Bcl-2 family mediated inhibition of apoptosis and drug resistance in B-cell chronic lymphocytic leukaemia. Br. J. Haematol. 114:2001;70-77.
26. Wittmann S., Bali P., Donapaty S., Nimmanapalli R., Guo F., Yamaguchi H., Huang M., Jove R., Wang H.G., Bhalla K. Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis. Cancer Res. 63:2003;93-99.
27. Yu C., Rahmani M., Dai Y., Conrad D., Krystal G., Dent P., Grant S. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process. Cancer Res. 63:2003;1822-1833.
28. Dai Y., Dent P., Grant S. Induction of apoptosis in human leukemia cells by the CDK1 inhibitor CGP74514A. Cell Cycle. 1:2002;142-143.
29. Ferri K.F., Kroemer G. Organelle-specific initiation of cell death pathways. Nat. Cell Biol. 3:2001;E255-E263.
30. O'Connor D.S., Grossman D., Plescia J., Li F., Zhang H., Villa A., Tognin S., Marchisio C., Altieri D.C. Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. Proc. Natl. Acad. Sci. U. S. A. 97:2000;13103-13107.
31. Bible K.C., Kaufmann S.H. Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res. 56:1996;4856-4861.
32. Boix J., Fibla J., Yuste V.J., Piulats J.M., Llecha N., Comella J.X. Serum deprivation and protein synthesis inhibition induce two different apoptotic processes in N18 neuroblastoma cells. Exp. Cell Res. 238:1998;422-429.
33. Ratan R.R., Murphy T.H., Baraban J.M. Macromolecular synthesis inhibitors prevent oxidative stress-induced apoptosis in embryonic cortical neurons by shunting cysteine from protein synthesis to glutathione. J. Neurosci. 14:1994;4385-4392.
34. Polymenis M., Schmidt E.V. Coupling cell division to cell growth by translational control of the G1 cyclin CLN3 in yeast. Genes Dev. 11:1997;2522-2531.
35. Hall D.D., Markwardt D.D., Parviz F., Heideman W. Regulation of the Cln3-Cdc28 kinase by cAMP in Saccharomyces cerevisiae. EMBO J. 17:1998;4370-4378.
36. Gil-Gomez G., Berns A., Brady H.J. A link between cell cycle and cell death: Bax and Bcl-2 modulate Cdk2 activation during thymocyte apoptosis. EMBO J. 17:1998;7209-7218.
37. Hakem A., Sasaki T., Kozieradzki I., Penninger J.M. The cyclin-dependent kinase Cdk2 regulates thymocyte apoptosis. J. Exp. Med. 189:1999;957-968.
38. Park D.S., Farinelli S.E., Greene L.A. Inhibitors of cyclin-dependent kinases promote survival of post-mitotic neuronally differentiated PC12 cells and sympathetic neurons. J. Biol. Chem. 271:1996;8161-8169.
39. Padmanabhan J., Park D.S., Greene L.A., Shelanski M.L. Role of cell cycle regulatory proteins in cerebellar granule neuron apoptosis. J. Neurosci. 19:1999;8747-8756.
40. Golstein P., Ojcius D.M., Young D.-E. Cell death mechanisms and the immune system. Immunol. Rev. 121:1991;29-63.
41. Dallaporta B., de Pablo M., Maisse C., Daugas E., Loeffler M., Zamzani N., Kroemer G. Proteasome activation as a critical event of thymocyte apoptosis. Cell Death Differ. 7:2000;368-373.
42. Pittman R.N., Wang S., DiBenedetto A.J., Mills J.C. A system for characterizing cellular and molecular events in programmed neuronal cell death. J. Neurosci. 13:1993;3669-3680.
43. Schulz J.B., Weller M., Klockgether T. Potassium deprivation-induced apoptosis of cerebellar granule neurons: a sequential requirement for new mRNA and protein synthesis, ICE-like protease activity, and reactive oxygen species. J. Neurosci. 16:1996;4696-4706.
44. Matranga C.B., Shapiro G.I. Selective sensitization of transformed cells to Flavopiridol-induced apoptosis following recruitment to S-Phase. Cancer Res. 62:2002;1707-1717.
45. Knockaert M., Meijer L. Identifying in vivo targets of cyclin-dependent kinase inhibitors by affinity chromatography. Biochem. Pharmacol. 64:2002;819-825.
46. Davido D.J., Leib D.A., Schaffer P.A. The cyclin-dependent kinase inhibitor roscovitine inhibits the transactivating activity and alters the posttranslational modification of herpes simplex virus type 1 ICP0. J. Virol. 76:2002;1077-1088.
47. Ljungman M., Paulsen M.T. The cyclin-dependent kinase inhibitor Roscovitine inhibits RNA synthesis and triggers nuclear accumulation of p53 that is unmodified at Ser15 and Lys382. Mol. Pharmacol. 60:2001;785-789.